Purpose: This study was intended to assess the ability of restaging gallium scanning to distinguish between patients with residual radiographic abnormalities who still have active Hodgkin's disease (HD) and those who are truly complete responders. Early identification of the former patients might increase the success of secondary salvage therapy.
A SIGNIFICANT PERCENTAGE of patients with advanced Hodgkin's disease (HD) fail to achieve complete remission (CR) with induction chemotherapy, or relapse following initial therapy. Response to induction chemotherapy is the single most important prognostic factor; patients who fail to achieve CR have a uniformly dismal prognosis." 2 Unfortunately, confusion exists over how to classify patients who have had shrinkage of their disease, but in whom residual abnormalities persist on conventional radiographs or computed tomographic scans. Such patients have been labeled as partial responders. Most have only residual fibrosis, but some have active HD and actually represent occult induction failures. Few clinical tools are available to help identify patients in apparent CR or partial remission (PR) who have occult residual disease. For example, the majority of patients who present with mediastinal HD have evidence of resid-pared with 8% for those with positive restaging scans (P < .001). The 4-year actuarial overall survival (OS) rate was 100% for those with negative scans compared with 51% for gallium-positive patients (P = .001). Twentyfour patients had residual chest x-ray or computed tomographic scan abnormalities. Calculated negative and positive predictive values for gallium scanning are 92% and 90%, respectively, compared with values of 48% and 83% for computed tomographic scanning.
Conclusion: Restaging gallium scans separate complete responders from induction failures with a high degree of accuracy. Gallium scanning is clearly superior to computed tomography in this regard. Patients with advanced HD who have positive restaging gallium scans after induction chemotherapy should be classified as induction failures and are highly unlikely to be cured with involved-field low-dose radiotherapy.
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ual mediastinal abnormalities on posttreatment plain chest films and/or chest computed tomographic scans. Computed tomographic image characteristics and mediastinal mass regression rates are not capable of distinguishing residual active lymphoma from fibrosis in these patients."s Residual lymphangiographic abnormalities are equally unlikely markers of active disease in the abdomen. 6 Gallium scanning, on the other hand, may be capable of discriminating between residual viable tumor and benign fibrous tissue. Gallium scanning has been identified as a sensitive and specific imaging modality for the pretreatment evaluation of patients with HD.
7 " 8 Several reports have also suggested the potential usefulness of gallium scanning following treatment of patients with both Hodgkin's and non-Hodgkin's lymphoma. 9 "
We report a retrospective review of patients with advanced HD treated at our institution who underwent gallium scanning as part of routine restaging following induction chemotherapy. Our study indicates that posttreatment gallium scans separate true complete responders from occult induction failures with a high degree of accuracy, particularly for patients with thoracic HD.
This study also demonstrates the lack of effectiveness of using low-dose consolidative radiotherapy for advanced HD patients in whom postinduction therapy gallium scans are positive. Such patients are considered induction failures and would generally require effective salvage therapy. Abbreviation: R, relapse.
MATERIALS AND METHODS
From 1983 to 1991, 178 patients with advanced HD were treated at Duke University Medical Center with induction combination chemotherapy. These included patients with stage III or IV disease, B symptoms, large mediastinal adenopathy, or relapsed disease after initial radiotherapy. During this time, gallium scans were obtained for the purposes of restaging on 45 HD patients, at the discretion of the attending medical or radiation oncologist. A retrospective review of the medical records was undertaken to identify patients who met the following criteria: (1) gallium scanning was performed immediately following induction chemotherapy as part of routine restaging before planned involved-field radiation therapy; (2) the patient had no signs or symptoms of active or progressive HD at the time of this restaging (clinical CR or PR); and (3) follow-up information was available for at least 6 months following restaging gallium scanning. Eleven patients who underwent posttreatment gallium scans for the evaluation of suspicious symptoms or clinically apparent relapse were excluded, as was one patient who died of treatment-related toxicity 4 months after a positive restaging gallium scan. Thirty-three patients met the inclusion criteria and form the basis for this report. Almost all of these patients had residual abnormalities on restaging computed tomographic scans, and the majority presented with advanced and/or relapsed disease and B symptoms ( Table 1) .
Treatment consisted of induction chemotherapy followed by consolidative radiotherapy (CMT) in 26 patients, chemotherapy alone (CT) in six, and radiotherapy alone (RT) in one. Chemotherapy regimens included mechlorethamine, vincristine, procarbazine, and prednisone (MOPP), doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), MOPP/ABVD, carmustine, cyclophosphamide, vinblastine, procarbazine, and prednisone (BCVPP), or etoposide, vinblastine, and doxorubicin (EVA). Radiotherapy was generally administered as low-dose, involved-field, consolidative radiotherapy with doses of 20 to 30 Gy (median, 24 Gy). The patient who was treated with RT alone and two CMT patients received high-dose radiotherapy with maximum doses of 40 to 45 Gy.
All patients underwent restaging 2 to 4 weeks following completion of 6 months of chemotherapy. Restaging procedures included physical examination, blood cell counts, computed tomographic scanning of the chest and abdomen, chest x-ray, and gallium scanning. Gallium scanning was performed with a standardized technique involving full-body planar imaging at 48 and 72 hours after injection of 10 mCi of gallium citrate. All gallium scans were reviewed by a senior nuclear medicine physician (R.J.R.) without knowledge of restaging computed tomographic scans or clinical outcome. Gallium intensity was scored at defined anatomic sites on a scale of 0 to 4 (Table 2) as described by Chen et al.'
2 Only focal areas of increased gallium uptake that were not consistent with normal physiologic uptake (bowel, salivary gland, breast tissue) were scored as galliumpositive. Diffuse, homogeneous increase in pulmonary gallium uptake, commonly seen following chemotherapy, was not scored as gallium-positive. Eleven of 33 patients underwent pretreatment gallium scans, all of which were positive. Patients were defined as being in CR at completion of induction chemotherapy if complete regression of all assessable disease had occurred. PR was defined as a greater than 50% reduction and stabilization of the size of clinically apparent disease, without any evidence for regrowth at completion of induction therapy. Patients with initial regression of disease followed by regrowth during the 6 months of initial chemotherapy were classified as induction failures. Results of restaging gallium scans were not considered when assigning response status following induction therapy for the purposes of this report. Relapse was defined as clinically apparent and/or histologically proven evidence of disease persistence or progression. Biopsy or autopsy proof of relapse was obtained in II of 14 relapsing patients. Actuarial overall survival (OS) and relapse-free survival (RFS) estimates were calculated by the method of Kaplan-Meier." The Cox-Mantle test was used to test survival time differences between groups for significance. 
Abbreviations: M, mediastinum; L, lung; I, iliac/inguinal; P, paraaortic; S, supraclavicular; C, cervical; A, axilla.
is 82%, with a 4-year actuarial RFS rate of 48%. For restaging gallium-negative patients, the 4-year actuarial OS rate is 100%, as compared with 51% for the restaging gallium-positive patients (P = .001). The 4-year actuarial RFS rate for gallium-negative patients is 75%, as compared with 8% for restaging gallium-positive patients (P < .001).
Twelve of 13 restaging gallium-positive patients have relapsed. Eleven of 12 relapsed within 8 months of the positive gallium scan, with the twelfth patient relapsing at 20 months. One restaging gallium-positive patient has not relapsed. He remains with no evidence of disease 8 years after a restaging gallium scan was positive in the mediastinum. This patient was treated with induction chemotherapy and involved-field irradiation (30 Gy) for clinical stage IIB nodular sclerosis HD involving the mediastinum.
Two of 20 restaging gallium-negative patients have relapsed. One patient experienced an isolated groin relapse 22 months following CMT for clinical stage IVB disease. Another patient experienced an isolated epitrochlear recurrence 27 months following CMT for relapsed clinical stage IIIA disease. Both patients had positive pretreatment gallium scans. Table 3 lists the patterns of gallium positivity and failure for the 14 relapsing patients. Eleven of 12 restaging gallium-positive anatomic sites were above the diaphragm; the majority of relapses in gallium-positive patients occurred at sites above the diaphragm. These observations emphasize both the increased sensitivity of gallium scanning above the diaphragm and the predilection for HD to involve supradiaphragmatic sites. All gallium-positive sites coincided with anatomic locations of pretreatment involvement with HD. In 10 of 12 restaging gallium-positive patients, the sites of relapse included the restaging gallium-positive sites. In six of these 10 patients, initial relapse occurred exclusively at gallium-positive sites; in four of the 10, relapse occurred at both gallium-positive and gallium-negative sites.
Only two of 12 gallium-positive patients had relapses that did not initially include a restaging gallium-positive site. Both patients had scans that were positive in the mediastinum. One of these patients died secondary to extensive hepatic involvement with HD 2 months after the positive gallium scan, without undergoing biopsy of the mediastinum. The second patient underwent biopsy of an enlarging, gallium-positive mediastinal mass. The biopsy showed a thymic cyst with no evidence of active HD. He relapsed 3 months later with involvement of the skull and subsequently developed pulmonary HD. His course suggests the possibility of sampling error in his mediastinal biopsy.
The mean interval between restaging gallium scan and relapse was 6 months for the 12 gallium-positive patients and 25 months for the two relapsing gallium-negative patients. Among restaging gallium-positive patients (gallium score, 1 to 4), the intensity of gallium uptake, as estimated by the scoring system listed in Table 2 , appeared to have no correlation with RFS or OS.
Twenty-four of 33 patients had residual thoracic radiographic abnormalities on chest x-ray or computed tomographic scan at the time of restaging (radiographic PR). The OS and RFS rates of this group were no different than for patients with no residual radiographic abnormality. Restaging gallium scans were positive in 11 of 24 and negative in 13 of 24. Ten of 11 gallium-positive, computed tomography-positive patients relapsed, as compared with one of 13 gallium-negative, computed tomography-positive patients. The 4-year actuarial RFS rate for the 13 gallium-negative patients is 80% versus 9% for the 11 gallium-positive patients (P < .001). The 4-year actuarial OS rate was 100% for the gallium-negative patients versus 44% for the gallium-positive patients (P = .003). Table 4 lists the failure rates for all 33 patients 309 according to the results of restaging computed tomographic scans (thoracic and abdominal) and gallium scans. From these data, the calculated positive and negative predictive values for gallium scanning are 92% and 90%, respectively. By comparison, the positive and negative predictive values for CT scanning are 48% and 83%, respectively.
Survival following relapse for gallium-positive patients was poor, with a 2-year actuarial OS rate of 42%. Both gallium-negative patients who relapsed are alive with short follow-up after relapse.
DISCUSSION
These data demonstrate that restaging gallium scans accurately identify patients who appear to be complete or partial responders to induction therapy, but who are actually induction failures. These patients share the poor prognoses of patients who are overt induction failures. Thus far in this report, we have spoken of these patients as having relapses of their HD, but in actuality they never had an adequate response to induction chemotherapy. Conversely, patients who have residual masses following induction therapy and are gallium-negative represent true complete responders and have an excellent prognosis when treated with CMT.
The utility of gallium imaging in patients with HD was incidentally identified in 1969 when gallium citrate was being investigated as a potential bone-scanning agent." Numerous reports have since documented the accuracy of gallium imaging in the pretreatment evaluation of patients with HD. 7 " 8 6 For patients with supradiaphragmatic HD, the sensitivity and specificity of high-dose gallium imaging are reported to be greater than 90%. However, gallium scanning is much less accurate in the investigation of infradiaphragmatic sites, due to the increased uptake of isotope normally seen in the liver, spleen, and intestines. The usefulness of gallium imaging following treatment for HD as a restaging procedure is not well documented. A few reports have suggested that posttreatment gallium scan results correlate with clinical outcome in patients with both HD and non-Hodgkin's lymphoma.'" Front et al 9 noted an excellent prognosis for HD patients with negative posttreatment gallium scanning, but report little data regarding patients with positive scans. Wylie et al" reported a good correlation between posttreatment gallium scan results and outcome in 25 patients with mediastinal HD. However, these reports do not address the issue of systematic restaging of asymptomatic patients who had apparently responded well to induction therapy, but had residual radiographic abnormalities. This is a common problem and poses a challenge for the clinician. It has been estimated that from 60% to 90% of patients with mediastinal presentations of HD will have residual radiographic abnormalities following RT or CMT for HD. In these irradiated patients, the outcome for those with residual mediastinal radiographic abnormalities is similar to those who have no residual abnormality. 3 5 To our knowledge, the frequency of residual radiographic mediastinal abnormalities in patients with mediastinal HD treated with induction combination chemotherapy has not been reported. In all probability, it is similar to that observed in patients treated with RT or CMT.
It has been suggested that failure to administer consolidative irradiation to chemotherapy-treated patients with residual radiographic changes leads to a high frequency of relapse. 4 In the Manchester series, one third of patients with residual radiographic abnormalities after treatment with CT relapsed, compared with 5% of those with a normal mediastinum. 7 In the recent Southwest Oncology
Group trial,'" the study design provided for consolidative radiation for all patients with residual radiographic abnormalities. Thus, most patients with residual radiographic abnormalities in the mediastinum following RT or CMT will do well. Following CT alone, such patients will apparently do less well. Our study defined a group of patients with residual radiographic abnormalities who will not do well with CMT, despite the fact that they appeared to have a good response to induction chemotherapy. These gallium-positive patients appear to have active disease in the residual radiographic abnormalities and have a poor outlook. Further evidence that a restaging gallium-positive scan signifies an induction failure is suggested by the rapidity with which such patients relapsed, nearly all having developed overt disease within 8 months of completion of induction chemotherapy.
In patients with advanced HD, a positive restaging gallium scan portends failure to respond not only at the gallium-positive site, but also frequently at other (often visceral) sites. This suggests that such patients have had only minimal cell kill with the initial course of induction chemotherapy and have a significant systemic burden of residual disease. Thus, they are highly unlikely to be effectively treated with consolidative radiotherapy (despite the apparent good clinical response to induction therapy) and probably need a different type of systemic treatment. It is conceivable that comprehensive high-dose irradiation would salvage a subset of these patients. However, if at initial presentation the indications for chemotherapy were appropriate (ie, stage IIIB or IV disease), it seems highly unlikely that these induction failures could be salvaged with comprehensive irradiation alone.
A few potential pitfalls concerning the use of restaging gallium scanning should be mentioned. First, the accuracy of gallium scanning below the diaphragm is inadequate due to normal uptake in the liver, spleen, and bowel. Special techniques including high-dose and/or singlephoton emission computed tomographic gallium imaging may overcome these difficulties in part. 20 Second, several pediatric cases have been reported in which gallium-positive enlarging mediastinal masses were noted several months following completion of chemotherapy. These masses were initially gallium-negative immediately following induction chemotherapy. Biopsy of a number of these cases demonstrated an apparent rebound thymic hyperplasia.
2 '
We recommend that gallium scans be obtained before and after induction chemotherapy for all patients with advanced HD. Patients in apparent clinical CR/PR who have positive restaging gallium scans following induction therapy have a significant burden of residual tumor and represent induction failures. Gallium scanning is clearly superior to computed tomographic scanning for identifying residual disease among patients with thoracic HD. Patients with positive restaging gallium scans will almost certainly relapse within several months of restaging, and have a poor prognosis. We recommend immediate biopsy of gallium-positive sites to document residual disease so that suitable salvage therapy may be instituted as soon as possible. These patients should be considered candidates for more aggressive forms of therapy, including highdose chemotherapy and bone marrow transplantation.
